Table 1. Relative Inhibition of A549 Cells 24, 48, and 72 h after Treatment^a.

treatments	24 h	48 h	72 h
Roscovitine	31.8 ± 6.1	47.3 ± 6.8	50.5 ± 9
Roscovitine_Seq	29.6 ± 14	69.7 ± 14.9	73.7 ± 12.2
Ethaverine	28.3 ± 5.8	39.5 ± 9.5	50.2 ± 8.6
Ethaverine_Seq	29.1 ± 11.3	48.6 ± 14.5	60.2 ± 10.5
Papaverine	27.4 ± 7	33.0 ± 11.4	40.9 ± 10.2
Papaverine_Seq	26.0 ± 15.3	46.4 ± 12.6	41.4 ± 13.4
Rosco-Etha	48.3 ± 5.3	77.1 ± 10.2	87.5 ± 8.4
Rosco-Etha_Seq	43.8 ± 7.4	85.3 ± 4.3	92.3 ± 8.6
Rosco-Papa	44.6 ± 6	72.8 ± 9.9	81.6 ± 11.4
Rosco-Papa_Seq	38.6 ± 6	83.5 ± 5.2	89.7 ± 3.2

^aA549 cells were treated once with 9 μM Roscovitine, 11 μM Ethaverine, or 8 μM Papaverine alone or with combinations of 9 μM Roscovitine/11 μM Ethaverine (Rosco-Etha) or 9 μM Roscovitine/8 μM Papaverine (Rosco-Papa) or treated sequentially (“_Seq”) every 24 h with each compound or combinations. % Cell inhibition relative to the mock are represented as mean ± SEM.